Form 10-K IONIS PHARMACEUTICALS For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China makes small dent in deflation battle as supply-demand imbalance persists
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
February 20, 2025 5:50 AM ESTRaymond James analyst Gary Nachman lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $61.00) while maintaining a Strong Buy rating.
The analyst comments "Key Updates. 1) Wainua in ATTR-PN. AZN booked $42M in 4Q (+83% q/q; FY $86M), with ~$10M royalties to IONS (FY $20M). U.S. launch is progressing well with new-to-brand share ~40%; seeing good... More
